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Females have long been underrepresented in preclinical research and clinical drug trials.
Directives by the U.S. National Institutes of Health have increased female participation in
research protocols, although analysis of outcomes by sex remains infrequent. The long-held
view that traits of female rats and mice are more variable than those of males is discredited,
supporting equal representation of both sexes in most studies. Drug pharmacokinetic analysis
reveals that, among subjects administered a standard drug dose, women are exposed to
higher blood drug concentrations and longer drug elimination times. This contributes to
increased adverse drug reactions in women and suggests that women are routinely overmedicated and should be administered lower drug doses than men. The past decade has seen
progress in female inclusion, but key subsequent steps such as sex-based analysis and sexspecific drug dosing remain to be implemented.

I

n the not too distant past, men were considered representative of the human species; differences from the male norm were viewed as
atypical or abnormal, just one aspect of a broader sexism that ranks among the most pervasive
human prejudices (Perry and Albee 1998). The
notion that women and girls were inferior to
men and boys was in play when agriculture
and sedentary cultures emerged (Ananthaswamy and Douglas 2018), with the status of
women lower than that of men from the dawn
of recorded history (Rosen 1971; Morsink
1979). Sex bias persists today in virtually all

walks of life, creating an environment that disadvantages women.
Women and nonhuman female mammals
have been given short shrift in biomedical research. Until recently, the research community
labored under the misguided assumption that
information garnered from studies of males
could be generalized without modiﬁcation to
females. Since then, sex differences in mechanisms underlying basic biological processes,
from pain signaling (e.g., Mogil et al. 2003; Sorge
et al. 2015) to synaptic inhibition (Huang and
Woolley 2012), to drug metabolism (described
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below), have been detailed with important consequences for women’s health (Heinrich 2001;
Klein et al. 2015).
The belief that hormonal variations associated with estrous and menstrual cycles renders
females more variable than males—now discredited (Mogil and Chanda 2005; Prendergast
et al. 2014; Becker et al. 2016)—discouraged inclusion of women and female rodents in experimental protocols, negatively impacting the
quality of medical care for women. Mazure and
Jones (2015) provide a detailed chronology of
changes instituted by the U.S. National Institutes of Health (NIH) to address sex bias in
human medical research, and provide a comprehensive list of actions needed to remove remaining barriers to ensure appropriate consideration
of sex as a biological variable (SABV) in biomedical studies.
Here we review historical and current trends
of female inclusion in preclinical and clinical
research, evolving policies aimed at increasing
participation of females in biomedical research,
and ongoing deﬁcits in analysis with sex or gender as a factor. The assumption that periodic
ﬂuctuations in hormone secretion compromise
female participation in scientiﬁc studies is discredited, and the pharmacological basis of human sex differences in adverse drug reactions
(ADRs) is explored.
HISTORICAL ANALYSIS

Inclusion of both sexes in research studies has
been consistently low (∼15%) over a 100-year
interval (Fig. 1A; Beery and Zucker 2011). In
the early to mid-twentieth century, the majority
(60%–80%) of articles dealing with nonhuman
mammals failed to report the sex of research
subjects used in biological research. Since then,
the percent of articles omitting subject sex has
markedly decreased, but has been accompanied
by a concomitant increase in the percent of articles reporting the exclusive use of males.
Inclusion of women in clinically relevant research has been marginally to substantially better over the past half century (Beery and Zucker
2011). Between 1949 and 1989, 32%–45% of
studies incorporated both male and female sub2

jects, with a marked increase to >60% in 1999
and 2009. Articles with sex unspeciﬁed declined
from over 20% between 1949 and 1979, to ∼7%
between 1989 and 2009.
CHANGES IN THE PAST DECADE: SEX BIAS

In 2009, we documented extensive male bias in
research on humans and nonhuman mammals
in eight of ten surveyed biological subdisciplines
(Beery and Zucker 2011). The ratio of articles
reporting on only males versus only females was
most skewed in the ﬁelds of neuroscience (5.5:1)
and pharmacology (5:1)—two research domains
with strong preclinical relevance. A female skew
was present only in studies of reproduction
(1:1.6), and in immunology (1:2.2). Subject sex
was often not reported in publications in 2009.
Sex was omitted in 22%–42% of articles in neuroscience and physiology; at least 92% of articles
in the behavior, endocrinology, and pharmacology categories speciﬁed sex of experimental animals or tissues (Beery and Zucker 2011).
In 2016, a U.S. National Institutes of Health
policy change (NOT-OD-15-102; NIH) required investigators to consider SABV in grant
applications. Woitowich and Woodruff (2019)
assessed the short-term impact of this directive
by surveying attitudes about the 2016 policy and
perceptions regarding its implementation
among NIH study section members in 2016
and 2017. A majority of respondents considered
it important for NIH-funded research to consider SABV and thought it would improve rigor
and reproducibility of ﬁndings. The percentage
of grant applications that successfully addressed
and incorporated the policy increased over this
span.
A follow-up study analyzed articles in nine
biological disciplines in 2019 to compare with a
similar survey a decade earlier, and to assess the
extent of incorporation of SABV in the years after
the 2016 NIH directive (Woitowich et al. 2020).
The percent of studies that included both sexes
increased across pooled subdisciplines (Fig. 1B),
with signiﬁcant gains in many but not all speciﬁc
ﬁelds (e.g., neuroscience but not pharmacology).
Overall, sex-inclusive research practices have increased since 2009, although male bias remains in
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Historical trends
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Figure 1. Sex bias in research subjects tested over time. (A) Sampling of mammalian studies published in two

physiology journals over the past century reveals that including both sexes is not the norm. Decreased omission of
the sexes of research subjects (“unspeciﬁed”) over time coincides with an increase in reports of male-only studies.
Historical data through 2009 are from Beery and Zucker (2011) (reprinted with permission from the authors).
2019 data from the Journal of Physiology (London) were obtained from the supplementary data ﬁle in Woitowich
et al. (2020) (reprinted with permission from the authors) (note the Journal of Pharmacology and Experimental
Therapeutics was not sampled for this year). (B) Across biological science subdisciplines surveyed, more 2009
studies examined only males than examined females or both sexes. By 2019, studies involving both sexes in at least
one part of the study were signiﬁcantly more common. This pattern was evident in some subdisciplines and not
others. For example, there was an increase in sex-inclusive articles in neuroscience, but no such increase in
pharmacology.  p < 0.0001; NS = not signiﬁcant.

several biological disciplines (Woitowich et al.
2020), and has increased in some ﬁelds (e.g., cardiovascular research [Ramirez et al. 2017]). In
neuroscience, these gaps appear more prevalent
for research performed in some species (e.g., rats,
ferrets), but do not currently directly reﬂect funding source (Mamlouk et al. 2020). Most reports of
single-sex male studies did not provide a rationale
for excluding females (Woitowich et al. 2020), but
justiﬁcation for female exclusion still sometimes
invoked the belief that females exhibit cyclicitydriven variability (now discredited, see below).

LACK OF CHANGE IN THE PAST DECADE:
SEX-BASED ANALYSIS

Whereas inclusion of females has improved over
the past decade, there has been no concomitant
increase in the percentage of studies on both sexes
that analyze results with sex or gender as a factor in
analyses, and fewer than half of sex-inclusive studies make reference to any such analysis (Fig. 2;
Mamlouk et al. 2020; Woitowich et al. 2020).
Thus, improved female inclusion has not yet translated into increased reporting of female biology.
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Figure 2. Lack of progress in analysis of ﬁndings by sex. While inclusion of both sexes increased from 2009 to

2019, there was no change in sex-speciﬁc analysis of the data: across ﬁelds, less than half of the studies that used
both sexes reported any analysis by sex. Separate analysis of nine biological subdisciplines showed only the ﬁeld of
pharmacology increased in percentage of sex-based analyses, but this needs to be understood in the context of a
ﬁeld that has not increased inclusion of females. In other words, when that minority of papers in this ﬁeld do
include females (see Fig. 1B), they are likely to look for sex differences. (Data are from Beery and Zucker 2011 and
Woitowich et al. 2020; reprinted, with permission, from the respective authors.)

The lack of sex-based analyses in sex-inclusive studies is potentially problematic. Males
and females should not be pooled in analysis
without—at a minimum—screening for sex differences (and reporting this screen); otherwise,
experimental power may be lost (Beery 2018;
Buch et al. 2019). When sex differences are
present, inclusion of sex as a factor in analysis
allows authors to identify these differences, as
well as to increase the power to detect main
effects of manipulations or treatments in the
presence of sex differences in mean values
(Beery 2018). Exploratory analysis of sex effects
using factorial designs can assess the main
effects of treatment and subject sex with effectively the same power as pairwise tests, without
increased sample size (Collins et al. 2014; Buch
et al. 2019). In the case where there is an interaction between sex and the main variable of interest, additional samples may be needed, and
testing designed to capture sex differences will
be biologically meaningful (Becker et al. 2005).
4

Fears of the need for doubled sample sizes
(or more) in the presence of sex differences are
thus unfounded. When sex differences are absent or when they are present without a sex ×
treatment interaction, no sample size increase is
needed (Beery 2018; Buch et al. 2019). When
both sex differences and a sex × treatment interaction are present (i.e., the situation requiring
the largest sample size increases), a recent model
revealed necessary increases of only 14%–33%
under different conditions to include both sexes,
even after statistical correction for the use of
multiple factors (Buch et al. 2019).
The actual prevalence of sex differences in
biology remains unknown, in part because there
have been so few systematic surveys of the topic.
This gap in reporting suggests that known sex
differences are just the tip of the iceberg. To
improve the validity of preclinical and clinical
research, it is not enough simply to include females in research studies; one must also examine
whether there are effects of sex/gender. Several
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guides for researchers to analyze sex differences
now exist (Becker et al. 2005; Beltz et al. 2019;
Buch et al. 2019).
FEMALE RODENTS ARE NOT A LIABILITY IN
PRECLINICAL RESEARCH

The long-standing assumption that the estrous
cycle renders females intrinsically more variable
than males may be the single greatest contributor to the sex biases cataloged in the preceding
section (Mogil and Chanda 2005). The underrepresentation of female animals in biomedical
research is based on the assumption that, for any
given trait, females exhibit more variability than
males, and therefore must be tested at each of
four stages of the estrous cycle to generate reliable data (Wald and Wu 2010). Satisfying this
requirement would quadruple the number of
females compared to studies employing males,
thereby increasing experimental effort and cost.
However, the question of whether such sex differences in variability even exist had not been
addressed until recently.
In an assessment of more than 8000 individual measurements collected on 40 different
mouse strains in three different laboratories, researchers found that females tested at random
points in their estrous cycles were no more variable than males on an acute thermal pain test;
no sex differences in variability measures were
observed in acute and tonic chemical nociception tests (Mogil and Chanda 2005). This inference transcended measures of pain, evidenced
by assessment of variability between male and
female mice on ∼10,000 morphological, physiological, and behavioral traits (Prendergast et al.
2014). This analysis focused on measures obtained without regard for the stage of the estrous
cycle, thus maximizing any supposed female
variability. Across this diverse array of traits, female variability was shown to be no greater than
that of males even when estrous cycles were not
monitored, thereby eliminating the barrier that
fostered underrepresentation of female rodents
in biomedical research (Fig. 3A).
The analysis also examined coefﬁcients of
variation (CVs) sorted into 30 broad trait categories but found no systematic pattern of sex-

biased CVs—a similar conclusion was reached
from an analysis of a set of >2 million data
points, across 218 traits measured from
>26,000 mice (International Mouse Phenotyping Consortium; Zajitschek et al. 2020). An evaluation of variability in gene expression, performed on 293 microarray data sets from mice
and humans, found gene expression in males to
be slightly more variable than that of females,
although the difference was small (Fig. 3B; Itoh
and Arnold 2015). The most common tissue
source for this analysis was brain, which showed
either a slight male bias in CV or no difference.
Distinct patterns of sex differences in variance
were identiﬁed in individual organs: in most
cases CVs were higher in males (kidney, adrenal,
skeletal muscle), but variance was greater in females in one tissue—spleen (Itoh and Arnold
2015). Overall, the report concluded that variability in gene expression was no greater in females than males.
An analogous meta-analysis, using similar
methods, was performed focused on neuroscience-relevant measures in male and female rats
(Becker et al. 2016). Evaluating over 6000 trait
measures, the authors found no overall differences in variability (Fig. 3C). As in prior reports,
the analysis identiﬁed individual trait categories
in which CVs were greater in one sex; and again,
this occurred more often in males. Indeed, the
authors found that even in the subset of ∼300
traits that were measured at known phases of the
estrous cycle, segregating data by cycle day did
not yield a reduction in variability of female data
(Fig. 3D). Taken together, results from metaanalyses of data sets in multiple species and
across diverse research domains are characterized by a consistent failure to support the hypothesis that females are intrinsically more
variable than males.
Changes in physiology and behavior across
the estrous cycle are, however, well-documented
in female rodents (Krzych et al. 1978; Barthelemy et al. 2004); indeed, these observations presumably fueled the notion that females must be
more variable (and thus more difﬁcult to study).
How, then, do these well-established estrous
ﬂuctuations fail to result in increased variability
in females? A possible answer lies in closer ex-
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indicates coefﬁcients of variation (CVs; standard deviation [SD]/mean) for phenotypic traits (n = 9932) of male (blue) and
female (yellow) wild-type mice as reported in 293 peer-reviewed articles published between 2009 and 2012 (Prendergast
et al. 2014). Green shading indicates overlapping areas of yellow and blue histograms. Bottom panel depicts CV ratios
(CVfemale/[CVfemale + CVmale]) for traits in the top panel. The CV ratio distribution ranges from 0.0 to 1.0, with CV ratios
>0.5 indicating greater trait-speciﬁc variance in females, and CV ratios <0.5 indicating greater variance in males. (B) CV
comparisons in microarray data sets. Histograms depict log2 transformed male-to-female CV ratios across ∼2.7 million
human and ∼2.4 million mouse microarray probes. In most bins, slightly more probes showed CVmale > CVfemale (Itoh and
Arnold 2015). (C) CV comparisons in laboratory rats. Histogram depicting CV ratios for 6252 traits in laboratory rats,
parsed into ﬁve broad trait categories. CV ratios were male biased for electrophysiology and neurochemistry measures, and
female biased for nonbrain measures. (D) Estrous cycle stage did not affect trait variability. Among rats examined in panel C,
even when data were aggregated by stage of the estrous cycle, CVfemale did not differ from CVmale (Becker et al. 2016). (Data
used under Creative Commons Attribution 4.0 International [CC BY 4.0: https://creativecommons.org/licenses/by/4.0].)

Figure 3. Trait variability is no greater in female than male mice. (A) Trait variability comparisons in mice. Top panel
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amination of the sources of variance within each
sex. Whereas a potent source of female variability may be found in hormonal ﬂuctuations over
the ovulatory cycle (Quinlan et al. 2010; Datta
et al. 2016), the sources and patterns of male
variability have not been systematically evaluated, let alone characterized. Accounting for the
overall absence of sex differences in variability is
warranted. The magnitude of variance associated with the estrous cycle may be sufﬁciently
small as to have little impact; alternatively, trait

A 180

variability of males over several consecutive days
may simply be as great as that of females over the
estrous cycle. Potential sources of this “hidden”
male variance were investigated by performing
time-series analyses of locomotor activity and
body temperature recorded continuously over
the estrous cycle of female mice and in yoked
males (Smarr et al. 2017). Overall variability in
circadian power was comparable between the
sexes for both traits. Remarkably, infradian variability (variance across days) was greater in fe-
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Figure 4. Female mice do not exceed males in variability of activity, body temperature, or food intake. (A) Box plots
of the daily variability in locomotor activity (LA), and (B) core body temperature (CBT) of female and male mice
housed in a 12L:12D light:dark cycle indicate that males have a higher intra-animal daily range in LA and CBT. (C
and D) Food intake data within and between male (blue symbols) and female (yellow symbols) mice subjected to
schedules of food availability and reward over 4-day blocks (corresponding to the estrous cycle, which was not
monitored). Under increasing cost of feeding, females exceeded males in intra-individual variability, (D) but not (C)
interindividual variability. The overall variance did not differ by sex under any of the food reward schedules. Food
intake (FI) designations represent the delay in seconds after which responses delivered a 20 mg food pellet. (Data in
A and B are from Smarr et al. 2019; reprinted, with permission, from the authors. Data used under Creative
Commons Attribution 4.0 International [CC BY 4.0: https://creativecommons.org/licenses/by/4.0].)
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males and ultradian variability (variance within
days) was greater in males (Fig. 4A). The results
also indicated that, for any given trait, depending
on how data are collected (e.g., across multiple
days, in a single day, during a ﬁxed time span
within a single day), measures will capture variance from different sources. Exclusion of female
mice from studies may thus increase variance in
investigations in which measures are collected
over a span of several hours. Ultimately, this factor may limit generalization of ﬁndings from
males to females. Smarr and colleagues (2019)
also detailed sex differences in variance structure
within ingestive behavior. Mice of both sexes
were subjected to schedules of food availability
and reward over 4-day blocks. Females exceeded
males in intra-individual variability, but not interindividual variability (Fig. 4B). Overall, variance did not differ by sex under any of the food
reward schedules.
Thus, convergent evidence from multiple
species and across diverse traits fails to support
the hypothesis that females are more variable
than males. Mogil and Chanda (2005) speculated that “male mice [may] feature their own sexspeciﬁc variability.” Now that the default assumption of greater female variability has been
assessed and rejected, a productive new direction may lie in efforts to identify the sources of
variance that render males as variable as females,
and in many cases, more variable than females.
NEGLECT OF WOMEN IN BIOMEDICAL
RESEARCH HAS NEGATIVE HEALTH
IMPLICATIONS

Many currently prescribed drugs were approved
by the U.S. Food and Drug Administration
(FDA) with inadequate enrollment of female
animals in preclinical research, and women in
clinical trials. For example, the popular sedativehypnotic drug zolpidem (Ambien), was ﬁrst approved in 1992 with just 19 women and 49 men
(FDA NDA 19908) as the sole pre-approval assessment of the effect of sex on pharmacokinetics (PK), which revealed marked elevation of
drug concentrations in women and longer elimination times. Only after decades of post-marketing reports of cognitive deﬁcits in women
8

were sex-based dose adjustments recommended, at which point women were advised to receive half the zolpidem dose given men. Many
other drugs administered in equal doses to women and men require reevaluation for sex-speciﬁc
dose adjustments, but relevant data are lacking
for almost all currently prescribed pharmaceuticals. Zolpidem is but one of many drugs not
administered on an mg/kg of body mass basis;
women are given the same dose as men, despite
lower body weights and sex differences in drug
absorption, distribution, bioavailability, metabolism, and excretion. Consequently, women
may be overmedicated.
Across all drug categories, ADRs are substantially more common in women than men
(de Vries et al. 2019); more female ADR reports
were submitted in all regions of the world and all
age groups from 12 to 17 years and older (Watson et al. 2019). It is conceivable that some of the
increase in ADR reports for women might be
caused by the possible overmedication discussed
above. Women are also signiﬁcantly more likely
to be hospitalized secondary to an ADR (Tharpe
2011; Nakagawa and Kajiwara 2015; Damien
et al. 2016). This disparity is pervasive: 46% of
a large sample of drugs manifests signiﬁcant sex/
gender differences in ADRs (Yu et al. 2016).
Women over the age of 19 were 43%–69%
more likely than men to have an ADR recorded
by their general practitioner (Martin et al. 1998).
ADRs also peak 20 years earlier among women
than men (Martin et al. 1998). Frequently reported ADRs included nausea, headache, drowsiness, depression, excessive weight gain, cognitive deﬁcits, seizures, hallucinations, agitation,
and cardiac rhythm anomalies. Women are
more likely than men to use two or more medications concurrently ( polypharmacy), and more
unique medications per year, which may also
contribute to increased female ADRs (Manteuffel et al. 2014).
Biological, psychological, and cultural factors
contribute to the greater prevalence of ADRs in
women, including sex differences in PK and
pharmacodynamics (PD), endogenous sexspeciﬁc organizational and activational steroid
hormone exposure, sex differences in exogenous
steroid administration, higher rates of polyphar-
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macy in women, sex differences in the expression
of somatoform disorders, and sex differences in
reporting rates (Kando et al. 1995).
PK differs in men and women for many
drugs (Harris et al. 1995; Meibohm et al. 2002;
Schwartz 2003, 2007; Gandhi et al. 2004; Soldin
and Mattison 2009; Franconi and Campesi 2014,
2017), which affects drug efﬁcacy and toxicity
(Institute of Medicine (US) Committee on Understanding the Biology of Sex and Gender Differences 2001; Amacher 2014). Signiﬁcant sex
differences have been noted in PK in ∼28% of
bioequivalence studies (Chen 2000). But PK information is included in only a small minority of
approved drug labels (Fadiran and Zhang 2015);
fewer than 4% of drugs in the Physicians’ Desk
Reference list population PK information in labeling (Duan 2007).
To examine whether sex differences in PK,
speciﬁcally elevated drug exposure and longer
elimination times in women than men, are associated with clinically signiﬁcant sex differences
in ADRs, a literature survey was performed to
identify drugs for which sex differences in both
PK and ADRs had been examined (Zucker and
Prendergast 2020). The analysis identiﬁed hundreds of FDA-approved drugs with sex differences in PK, and 86 drugs with statistically signiﬁcant sex differences in PK, which also
reported data on ADRs that were analyzed by
sex (Fig. 5). PK differences commonly manifested in measures of the maximum drug concentration in the blood (Cmax) and area under the
curve (AUC), but also included distribution volume and measures of drug elimination rate (e.g.,
circulating half-life). Many drugs with pronounced sex differences in ADRs were excluded
from the analysis because PK data were not available, typically because the drug was approved
prior to the year 2000, or because sex-speciﬁc
analyses were not available in the FDA database.
The analysis also indicated that many sex differences in ADRs persisted even after corrections
for body weight were considered.
The correspondence of sex differences in PK
with sex differences in ADRs was striking. In 88%
of instances, a sex difference in PK was linked to a
similar sex difference in ADRs; PK-ADR concordance is summarized in Table 1. The sex differ-

ence in ADRs among these drugs is substantially
higher than the 46% sex difference in ADRs
across all drugs assessed without regard to PK
differences (reported by Yu et al. 2016). Thus,
including PK data in the consideration of ADRs
and stratifying analyses of drugs by the presence
and direction of PK differences greatly clariﬁes
patterns of sex differences in ADRs. Nearly all
(96%) drugs with higher PK values in women
were associated with a higher incidence of
ADRs in women than men, whereas only 29%
of drugs for which PK values of males exceeded
those of females did this sex difference positively
predict male-biased ADRs (Fig. 5). Indeed, even
in this small fraction of drugs with male-biased
PK, ADRs were more prevalent or severe in women. These data show an alarming pattern: elevated
drug concentrations and decreased elimination
times are far more common in women than
men. For drugs with female-biased PK, the clear
mapping of PK onto ADRs suggests that drugs
that exhibit female-biased PK present a major
health risk for women that is not prioritized by
the medical profession. An even stronger potential for risk lies in that far larger number of drugs
for which no data on PK sex differences exist.
The lack of attention to female subjects during the early stages of drug development may
have pervasive, unintended effects that contribute to the disproportionate occurrence of ADRs
in women. Drug development pipelines often
begin with preclinical modeling, in vitro experiments in human tissues and in vivo experiments in laboratory animal models (usually
mice). Inattention to sex and gender in the early
stages of drug development can create founder
effects that may bias drug efﬁcacy toward one
sex. If, during early stages of preclinical development, a drug is optimized and titrated speciﬁcally in cells or mice of one sex, then any sex
biases inherent in such model systems may be
propagated into later stages of drug development. For example, three of the four human
cell lines currently being used for SARS-CoV-2
(COVID-19) research are male (Takayama
2020). Disproportionate female-biased PK and
ADRs that are likely to emerge may reﬂect
echoes of sex-biased research decisions early in
the scientiﬁc process.
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All drugs evaluated
PK bias
Women
Men
n = 86 drugs

Drugs with published ADRs

n = 59

Phamacokinetics
Adverse drug reactions

ADR bias
Women
Men
No sex bias
n=7

Phamacodynamics
Sex-concordant ADRs (%)

n = 52

***

100

75
50
25
n = 52
0
PK > PK

n=7
PK > PK

Phamacokinetics

Figure 5. Relations between pharmacokinetics (PK) and adverse drug responses in humans. Sex differences in

PK were identiﬁed in 86 U.S. Food and Drug Administration (FDA)-approved drugs, 59 of which also yielded
data on sex differences in adverse drug reactions (ADRs). PK analyses identiﬁed greater drug exposure in women
(a female PK bias) for 52 (88%) of these drugs. Among these 52 drugs with female-biased PK, 50 also had femalebiased ADRs (96% concordance between PK and ADR biases). In contrast, only two of seven drugs with malebiased PK exhibited male-biased ADRs (29% concordance). (Data from Zucker and Prendergast 2020; reprinted,
with permission, from the authors.)
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Genito-urinary system, sex
hormones

Cardiovascular system

Blood and blood-forming organs

Alimentary tract, metabolism

World Health Organization
anatomical therapeutic chemical
category

AUC, CLT, t1/2

CLT
AUC, Cmax

AUC
AUC, Cmax,
CLT, t1/2
AUC, Cmax
CLT
CLT
CLT

Aspirin

Warfarin
Clopidogrel

Dabigatran
Torasemide

AUC, Cmax,
CLT
AUC, Cmax

Darifenacin
Trospium

Dofetilide
Mirabegron

AUC, Cmax
AUC, Cmax
AUC, Cmax,
CLT
SysExp
AUC, Cmax,
SysExp

Aliskiren
Losartan
Propranolol

Pravastatin
Amlodipine
Digoxin
Verapamil

CLT
AUC, Tmax
CLT
CLT

PK measureb

Liraglutide
Ranitidine
Rosiglitazone
Heparin

Druga

Cognitive impairments

Congenital heart disease
Edema, ﬂushing, palpitations
Mortality
Constipation, edema, fatigue,
headache
Diarrhea
‐
Dizziness, muscle pain,
headache, dry mouth
TdP
Treatment discontinuation
(CAN), treatment
discontinuation (CZE)
F > M, ADRs not speciﬁed

Headache, vomiting, nausea
‐
Fracture
Blood disorders, lymphatic
disorders, bleeding (60 yoa)
Elevated ﬁbrinogen
cardiovascular disease in
type II diabetics
Bleeding
Fracture, bleeding,
gastrointestinal symptoms,
inﬂammatory bowel disease
Bleeding
Hospitalization

Female-biased ADRs

-

-

-

-

-

-

-

Treatment discontinuation (UK)

Angina, mortality

Bleeding

Duodenal damage
-

Male-biased ADRs

Table 1. Summary of sex-biased pharmacokinetic (PK) measures and concordance with clinical adverse drug reactions (ADRs)
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Continued

Concordant

Concordant

Concordant
Concordant

Concordant
Discordant
Concordant

Concordant
Discordant
Concordant
Concordant

Concordant
Concordant

Concordant
Concordant

Concordant

Concordant
Concordant
Concordant
Concordant

PK-ADR
relation
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CLT
AUC
CLT
CLT
CLT

CLT
AUC, Cmax
AUC, Cmax
AUC, Cmax
CLT

Paclitaxel
Capecitabine
Inﬂiximab
Adalimumab
Morphine

Oxycodone
Buprenorphine
Tramadol
Zolmitriptan
Ketamine

Antiepileptics, anti-Parkinson’s

Anesthetics, analgesics

Antineoplastics,
immunomodulators

CLT, SysExp
CLT
AUC, Cmax
CLT
AUC, CLT

Levoﬂoxacin
Erythromycin
Voriconazole
Cyclosporin
Flurouracil

Anti-infectives

CLT, t1/2
Cmax
AUC, CLT
AUC, Cmax

Carbamazepine
Gabapentin
Perampanel
Pramipexole

AUC, CLT

Prednisone

Systemic hormonal preparations

PK measureb

Druga

World Health Organization
anatomical therapeutic chemical
category

Table 1. Continued

Cognitive impairment,
elevated LDL/HDL
Dizziness, somnolescence,
nausea
Dizziness, headache,
treatment, discontinuation
Nausea, fatigue

Depression, fatigue, hair loss,
mood swings, weight gain
Fluoroquinolone toxicity
TdP
Cardiac QTc symptoms
Stomatitis, leukopenia,
alopecia, diarrhea, mucositis
Myocardial infarction, death,
lesion, revascularization
Dose-limiting toxicity
Allergic reactions
Allergic reactions
Respiratory depression,
hypoxic sensitivity, emesis,
nausea
Nausea, pruritus, negative
affect
Sleep disturbance
Treatment discontinuation
Face and neck pressure
‐

Female-biased ADRs

Continued

Concordant

Concordant

-

Concordant

-

Discordant

Concordant
Concordant
Concordant
Concordant

Verbal learning,
subjective memory
-

Concordant

Concordant
Concordant
Concordant
Concordant

Concordant

Concordant
Discordant
Concordant
Discordantc
Concordant

Concordant

PK-ADR
relation

-

-

-

-

-

Male-biased ADRs
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Psychoanaleptics

Psycholeptics

World Health Organization
anatomical therapeutic chemical
category

Table 1. Continued
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CLT

AUC, Cmax
t1/2
AUC, Cmax,
CLT
AUC
CLT

CLT
CLT

CLT
AUC, CLT, t1/2
AUC, Cmax, t1/2

Risperidone

Aripiprazol
Diazepam
Zolpidem
Eszopiclone
Imipramine

Nortriptyline
Fluoxetine

Citalopram
Sertraline
Bupropion

Methylphenidate AUC

CLT
CLT

PK measureb

Olanzapine
Clozapine

Druga

Hyperprolactinemia,
neurological effects,
headache hypotension
Blood pressure, heart rate,
elongated QTc
Psychomotor impairment
Cognitive impairment, driving
impairment
Dysgeusia
Dry mouth, constipation,
sweating, tremor, treatment
discontinuation
Dry mouth
Hypercortisolemia, elevated
albumin, elevated
tryptophan, suicidal
ideation
Elevated ADH
Cholesterol, nausea, dizziness,
delusions
EEG abnormalities,
seizures
Anxiety disorder

Severe weight gain
Blood glucose, laxative use,
obesity, type II diabetes,
neutropenia, leukopenia,
weight gain

Female-biased ADRs

-

Dyspepsia, sexual dysfunction,
urinary frequency
-

-

Continued

Discordant

Concordant

Concordant
Concordant

Concordant
Concordant

Concordant
Concordant

Concordant
Concordant

-

Concordant

Concordant

Concordant
Discordant

PK-ADR
relation

-

Hypertension, increases in BMI,
elevated homocysteine, increased
basal metabolic rate, increased
plasma lipids, QTc symptoms,
blood dyscrasias, myocarditis,
cardiomyopathy
-

Male-biased ADRs
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14

CLT

Cannabis

Nausea
TdP
Visual attention deﬁcits,
reaction time deﬁcits,
driving impairments
Elevated copeptin,
hyponatremia
Increased subjective emotional
responses, problematic
cannabis use, introvertive
anhedonia

Female-biased ADRs

Concordant
Concordant

-

Concordant
Concordant
Concordant

PK-ADR
relation

-

-

Male-biased ADRs

(AUC) Area under the curve, (Cmax) maximum circulating concentration, (Tmax) time required to reach Cmax value, (t1/2) elimination
half-life, (CLT) clearance time, exposure, or plasma concentration after a ﬁxed time interval, (SysExp) systemic exposure.
a
Font style of drug name indicates direction of PK drug exposure bias: (normal font: F > M; bold font: M > F).
b
Font style of PK measure indicates direction of greater drug exposure (normal font: F > M; bold font: M > F).
c
No evidence of sex differences in ADRs.

CLT

MDMA

Miscellaneous

AUC, Cmax
Cmax
AUC, Cmax

PK measureb

Primaquine
Terfenadine
Fexofenadine

Druga

Antiparasitics
Respiratory

World Health Organization
anatomical therapeutic chemical
category

Table 1. Continued
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A number of steps might remediate this sex
disparity in health and well-being that stems
from female-biased ADRs. The high correlation
between elevated PK in women and increased
female ADRs suggests that for drugs with higher
female PK, the initial dose should be lower for
women than men and increased only if the lower
dose fails to achieve the desired therapeutic effect.
Establishing sex parity in subject enrollment
during the drug approval process should be explicitly identiﬁed as a long-term goal of the Department of Health and Human Services. The
decades-long pattern of neglect of female animals in preclinical research and underrepresentation of women in clinical trials and research
must be corrected; recent NIH oversight and
vigilance is an important step in the right direction that needs to be maintained.
CONCLUDING REMARKS

Until relatively recently, female animals and
women were woefully underrepresented in biomedical research. Beginning in the 1990s,
spurred by the NIH revitalization act and continuing in subsequent decades, a remedial effort
has increased inclusion of women and female
rodents in clinical and preclinical studies. An
increased emphasis on enrolling both sexes
emerged in the past decade, but a majority of
such studies still fail to consider sex or gender as
factors in their analyses; this continued omission represents a missed opportunity and is a
serious shortcoming. An increasing number of
studies has established that average trait variability is no greater in females than males, thereby removing the long-held, unsubstantiated bias
against inclusion of female rodents in research
protocols. In many instances, sex inclusion does
not require increases in sample size, but when
such increases are necessary, they are smaller
(e.g., 25% increase) than generally assumed.
The well-established increased susceptibility
of women to adverse drug reactions has now
been strongly correlated with substantial sex differences in drug PK; women given the same
drug dose as men routinely generate higher
blood concentrations and longer drug elimina-

tion times and thus may be chronically overmedicated. For drugs with known sex differences in PK, women should be administered
lower drug doses.
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